Get the Stockscreener App
44.88
3.60%
1.56
Supernus Pharmaceuticals Inc stock is traded at $44.88, with a volume of 1.05M.
It is up +3.60% in the last 24 hours and up +37.37% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$43.32
Open:
$43.49
24h Volume:
1.05M
Relative Volume:
1.39
Market Cap:
$2.52B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
41.96
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+5.13%
1M Performance:
+37.37%
6M Performance:
+35.79%
1Y Performance:
+30.31%
1-Day Range:
$43.49
$45.01
1-Week Range:
$41.78
$45.01
52-Week Range:
$29.16
$45.01
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
44.88 | 2.41B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Short Term Trend Reversal in Supernus Pharmaceuticals Inc. PossibleJuly 2025 PostEarnings & Consistent Income Trade Ideas - newsyoung.net
This Insider Has Just Sold Shares In Supernus Pharmaceuticals - simplywall.st
Insider Sell: Bethany Sensenig Sells 5,369 Shares of Supernus Ph - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 43.62 USD By Investing.com - Investing.com Australia
Supernus Pharmaceuticals stock hits 52-week high at 43.62 USD - Investing.com
Is Supernus Pharmaceuticals, Inc. exposed to political riskTrade Risk Report & AI Optimized Trade Strategies - mustnews.co.kr
Can Supernus Pharmaceuticals Inc. expand into new markets2025 Dividend Review & Fast Entry High Yield Tips - classian.co.kr
Published on: 2025-08-17 09:07:05 - metal.it
How high can Supernus Pharmaceuticals Inc. stock goJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Live market analysis of Supernus Pharmaceuticals Inc.July 2025 Movers & High Yield Equity Trading Tips - Newser
What moving averages say about Supernus Pharmaceuticals Inc.Rate Cut & Daily Risk Controlled Trade Plans - Newser
Is Supernus Pharmaceuticals Inc. stock ready for a breakoutMarket Growth Summary & Risk Managed Trade Strategies - Newser
Will Supernus Pharmaceuticals Inc. stock go up soonMarket Rally & Safe Entry Trade Reports - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyProfit Target & Advanced Swing Trade Entry Alerts - Newser
Technical signs of recovery in Supernus Pharmaceuticals Inc.Quarterly Trade Report & Comprehensive Market Scan Insights - Newser
Is Supernus Pharmaceuticals Inc. forming a bottoming baseMarket Performance Recap & Technical Confirmation Trade Alerts - Newser
Is Supernus Pharmaceuticals Inc. the Top Chart Pick This WeekInflation Watch & AI Powered Market Entry Strategies - sundaytimes.kr
Will Supernus Pharmaceuticals Inc. benefit from sector rotationJuly 2025 Movers & Long-Term Safe Investment Plans - newsimpact.co.kr
PNC Financial Services Group Inc. Acquires 726 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know | FinancialContent - FinancialContent
These Three Healthcare Cos. Could Inject New Life Into an Ailing Portfolio - TheStreet Pro
Analyzing net buyer seller activity in Supernus Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - Newser
Short Term Trend Reversal in Supernus Pharmaceuticals Inc. Possible [Portfolio Gains Report]Free Daily Stock Momentum Reports - 선데이타임즈
Supernus Pharmaceuticals' Accrual Ratio and Unusual Items Impact Earnings - AInvest
Statutory Profit Doesn't Reflect How Good Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are - Yahoo Finance
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade - Yahoo Finance
5 Insightful Analyst Questions From Supernus Pharmaceuticals’s Q2 Earnings Call - ca.finance.yahoo.com
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
Supernus Pharmaceuticals shares rise 1.48% intraday after Lotus Pharmaceuticals reported a 6% revenue increase in the first half of 2025. - AInvest
Supernus Announces Second Quarter 2025 Financial Results - ADVFN Brasil
How to recover losses in Supernus Pharmaceuticals Inc. stockFree Chart Alert System With Entry Targets - Newser
RSI + MACD Show Convergence for Supernus Pharmaceuticals Inc.High Conviction Intraday Stock Signals Detected - metal.it
Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionShort-Term Support and Resistance Forecast - Newser
CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals - TipRanks
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals Shares Dip Amid Growth Plans - TipRanks
Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
SUPN Stock Surge: What’s Driving It? - StocksToTrade
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today - Yahoo Finance
Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel - Investing.com Canada
Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fi - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD By Investing.com - Investing.com Australia
Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13% - AInvest
Supernus Pharmaceuticals Q2 CY2025 Financial Results: Exceeding Market ExpectationsNews and Statistics - IndexBox
Supernus: Q2 Earnings Snapshot - New Haven Register
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):